title: Early detection of response in small cell bronchogenic carcinoma by changes in serum concentrations of creatine kinase, neuron specific enolase, calcitonin, ACTH, serotonin and gastrin releasing peptide.
abstract: Creatine kinase (CK-BB), neuron specific enolase (NSE), ACTH, calcitonin, serotonin and gastrin releasing peptide (GRP) were measured in serum or plasma before and immediately after initiation of treatment in patients with small cell lung cancer (SCC). Pretherapeutic elevated concentrations of CK-BB were found in 82% of extensive disease patients and in 50% of patients with local disease. NSE was raised in 72% with extensive disease versus 14% of patients with local disease. Calcitonin and ACTH were raised in 27% and 28%, respectively, in all patients without significant difference between extensive and local disease patients. Serotonin was generally overall elevated in 10% and GRP in 7% but elevations were seen only in patients with extensive disease. Out of the four most frequently elevated substances at least one marker was elevated in 80% of all the patients, including 91% in extensive stage patients and 71% in limited stage patients. Frequent initial monitoring of the substances showed an increase in the concentrations of pretherapeutic elevated CK-BB and NSE on day 1 or 2 followed by a sharp decrease within 1 week. These changes were correlated to objective clinical response determined within 4-8 weeks. The results indicate that serum CK-BB and NSE are potential markers for SCC at the time of diagnosis and that changes in the concentrations during the first course of cytostatic therapy are promising as biochemical tests for early detection of response to chemotherapy.
authors.affiliation: Department of Internal Medicine C, Bispebjerg Hospital, Copenhagen, Denmark.
authors.forename: E
authors.initials: E
authors.lastname: Bork
authors.forename: M
authors.initials: M
authors.lastname: Hansen
authors.forename: P
authors.initials: P
authors.lastname: Urdal
authors.forename: E
authors.initials: E
authors.lastname: Paus
authors.forename: J J
authors.initials: JJ
authors.lastname: Holst
authors.forename: S
authors.initials: S
authors.lastname: Schifter
authors.forename: M
authors.initials: M
authors.lastname: Fenger
authors.forename: F
authors.initials: F
authors.lastname: Engbaek
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D002116:Calcitonin / Q000097:blood; D018288:Carcinoma, Small Cell / Q000097:blood* / Q000188:drug therapy; D003402:Creatine Kinase / Q000097:blood; D019886:Gastrin-Releasing Peptide; D005768:Gastrointestinal Hormones / Q000097:blood; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000188:drug therapy; D010455:Peptides / Q000097:blood; D010751:Phosphopyruvate Hydratase / Q000097:blood; D012701:Serotonin / Q000097:blood; D013997:Time Factors
chemical_list: D014408:Biomarkers, Tumor; D005768:Gastrointestinal Hormones; D010455:Peptides; D012701:Serotonin; D019886:Gastrin-Releasing Peptide; D000324:Adrenocorticotropic Hormone; D002116:Calcitonin; D003402:Creatine Kinase; D010751:Phosphopyruvate Hydratase